Abstracts tagged "psoriatic arthritis and pain"

Abstract Number: 1502 • 2019 ACR/ARP Annual Meeting
The Effect of Tofacitinib on Residual Pain in Patients with Psoriatic Arthritis
Maxime Dougados¹, Désirée van der Heijde ², Clifton Bingham ³, Peter Taylor ⁴, Lara Fallon ⁵, John Woolcott ⁶, Yves Brault ⁷, Lisy Wang ⁸ and Meriem Kessouri ⁷, ¹Cochin Hospital, Paris, France, ²Leiden University Medical Center, Leiden, Netherlands, ³Johns Hopkins University, Baltimore, MD, ⁴University of Oxford, Oxford, United Kingdom, ⁵Pfizer Inc, Montreal, QC, Canada, ⁶Pfizer Inc, Collegeville, PA, ⁷Pfizer Inc, Paris, France, ⁸Pfizer Inc, Groton, CT
Background/Purpose: Current treatments for PsA have proven effective in reducing patient (pt)-reported pain;1,2 however, residual pain often remains. Tofacitinib is an oral Janus kinase inhibitor…
Abstract Number: 1556 • 2019 ACR/ARP Annual Meeting
Exposure–Response Modeling of an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, BMS-986165, for Pain Visual Analog Scale Score, in Patients with Psoriasis and Musculoskeletal Symptoms
Jun Shen¹, Anjaneya Chimalakonda ¹, Miroslawa Nowak ¹, John Throup ¹, Subhashis Banerjee ¹ and Ihab Girgis ¹, ¹Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: BMS-986165 is an oral, selective inhibitor of TYK2, an enzyme that activates signal transducer and activator of transcription (STAT)-dependent cytokine signaling pathways, including the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].